RecruitingNCT07502664

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Sponsor

Ray Therapeutics, Inc.

Enrollment

25 participants

Start Date

Feb 19, 2026

Study Type

OBSERVATIONAL

Conditions

X-linked Retinoschisis Retinitis Pigmentosa Stargardt Disease Retinal Dystrophies Stargardt Macular Dystrophy Geographic Atrophy from Age-related Macular Degeneration

Summary

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records
Best-corrected visual acuity between 20/200 to HM in at least one eye.
Reasonably fluent in English or Spanish

Exclusion Criteria3

Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
Current pregnancy as reported by patient

Interested in this trial?

Get notified about updates and connect with the research team.